The Department of Biomedicine

News archive for The Department of Biomedicine

Stroke patients have particular high risk of thrombotic events caused by platelet (thrombocyte) activation, which may lead to new infarctions. Secondary treatment of these patients with anti-platelet therapy consisting of aspirin and dipyridamole is therefore a common protocol. Recent results on the mechanism of action of this treatment suggest that regulation of platelet shape change, the... Read more
At the Department of Biomedicine a postdoctoral position is vacant for the duration of two years. The position is financed by the University of Bergen (UiB) and The Research Council of Norway and is attached to the Proteomics Unit UIB (PROBE http://www.uib.no/rg/probe) at the Department of Biomedicine. The work place will be at the Building for Basic Biological Research, Jonas Lies Vei 91.
New findings can lead to a more optimalised treatment of brain cancer.
Nature article related to cell communication.
New molecular knowledge can give hope for patients with Føllings disease.
An access to a better understanding of the human mind and the manner of our behaviour?
The board of FUGE (the Functional Genomics programme of Norway) has granted 2,3 mill NOK to be distributed to research projects in order stimulate use of bio bank material in proteomics research. This is part of the effort to stimulate researchers to utilize multiple FUGE platforms in their research and to encourage contact and interdisciplinary cooperation between the different technology... Read more
PROBE, together with the Department of Molecular Biology will hold a course on Quantitative Proteomics in Bergen June 7-11th 2010. The course, which requires basic knowledge (theoretical and practical) in proteomics will address state of the art proteomics techniques through lectures, practical work and demonstrations. The course is supported by Nordforsk.
Discovery of the "Golgi-bypass" provides new insight into how disease-related proteins are transported to the cell surface.
Professor James Lorens and his group use nanotechnology to study tissue production and cancer development.